Gilead Sciences, Inc. (NASDAQ:GILD) Stock Holdings Trimmed by Clifford Swan Investment Counsel LLC

Clifford Swan Investment Counsel LLC lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 7.0% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 60,214 shares of the biopharmaceutical company’s stock after selling 4,548 shares during the quarter. Clifford Swan Investment Counsel LLC’s holdings in Gilead Sciences were worth $5,562,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Avior Wealth Management LLC grew its position in Gilead Sciences by 1.2% in the 3rd quarter. Avior Wealth Management LLC now owns 9,422 shares of the biopharmaceutical company’s stock valued at $782,000 after buying an additional 108 shares in the last quarter. Southland Equity Partners LLC lifted its stake in shares of Gilead Sciences by 3.6% in the 4th quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company’s stock worth $289,000 after acquiring an additional 110 shares during the period. Concord Asset Management LLC VA lifted its stake in shares of Gilead Sciences by 3.8% in the 3rd quarter. Concord Asset Management LLC VA now owns 3,056 shares of the biopharmaceutical company’s stock worth $256,000 after acquiring an additional 111 shares during the period. Berkshire Bank boosted its holdings in shares of Gilead Sciences by 3.4% in the fourth quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company’s stock valued at $314,000 after acquiring an additional 111 shares in the last quarter. Finally, TFB Advisors LLC increased its stake in shares of Gilead Sciences by 1.2% during the third quarter. TFB Advisors LLC now owns 9,397 shares of the biopharmaceutical company’s stock valued at $788,000 after acquiring an additional 116 shares during the period. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of GILD opened at $114.31 on Friday. The business’s 50-day moving average is $97.42 and its 200-day moving average is $90.05. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The company has a market capitalization of $142.46 billion, a price-to-earnings ratio of 308.95, a P/E/G ratio of 0.71 and a beta of 0.18. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $114.77.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Equities research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Friday, March 14th. This represents a $3.16 dividend on an annualized basis and a yield of 2.76%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s payout ratio is 854.05%.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Truist Financial increased their price target on Gilead Sciences from $83.00 to $97.00 and gave the company a “hold” rating in a research note on Friday, November 8th. Citigroup started coverage on Gilead Sciences in a research note on Thursday, November 14th. They set a “buy” rating and a $125.00 target price for the company. The Goldman Sachs Group lifted their target price on Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a report on Wednesday, February 12th. Royal Bank of Canada upped their price target on shares of Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a report on Wednesday, February 12th. Finally, Maxim Group cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. Eleven investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $102.08.

Insiders Place Their Bets

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the transaction, the chief financial officer now owns 129,873 shares in the company, valued at approximately $11,863,898.55. This represents a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders have sold a total of 293,356 shares of company stock valued at $29,166,240 in the last three months. Insiders own 0.16% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.